Alphatec Spine’s first-quarter preliminary consolidated revenues up 25 read more .6 percent Alphatec Holdings, Inc. , the parent firm of Alphatec Spine, Inc., a medical device company that styles, develops, manufactures and marketplaces products for the medical procedures of spine disorders, with a concentrate on treating conditions linked to the aging backbone, announces today that, based on preliminary financial data, the Company will survey record consolidated quarterly revenues of approximately $38.4 million for the first quarter 2010, an increase of 25.6 percent from the $30.6 million reported for the first quarter 2009, and a sequential enhance of 5.0 percent over fourth one fourth 2009 revenues of $36.6 million.

And Europe that annually suffer acute porphyria episodes, and 500 patients are suffering from recurrent debilitating episodes approximately. Treatment plans for AIP patients experiencing an acute attack are limited, and include the usage of heme preparations that show limited efficacy and are associated with a true number of complications. Presently, there are no medications available to prevent episodes from occurring. Alnylam's approach is to knockdown ALAS-1, an enzyme upstream of porphobilinogen deaminase , in hepatocytes. RNAi-mediated silencing of hepatocyte ALAS-1 could reduce the abnormal production of the toxic heme intermediates, particularly aminolevulinic acid and porphobilinogen , which mediate the symptoms and disease pathology in these patients.